BINSA Act
Latest action (2 Jun 2026): Introduced
What this bill does
H.R. 9102, the Biotech Investment National Security Act of 2026 (BINSA Act), would amend the Defense Production Act of 1950 to add biotechnology to the list of technology areas subject to outbound investment screening. Specifically, it expands the definitions of "prohibited technology" and "notifiable technology" to include research, development, manufacturing, or commercialization of pharmaceutical products, biological products, and therapeutic compounds, including drug discovery platforms, clinical research capabilities, biologics manufacturing, and related intellectual property. It also adds licensing a prohibited technology from a covered foreign person as a covered transaction type.
The bill directs the Treasury Secretary, within one year and after consulting with the Departments of Health and Human Services and Defense and the Director of National Intelligence, to issue a rule further defining the biotechnology sector for these purposes, prioritizing licensing deals, joint ventures, and equity investments involving drug discovery, clinical development, and manufacturing know-how, while excluding agricultural biotechnology, unrelated industrial fermentation, and basic academic research. It also requires a Defense Department report within 60 days assessing whether U.S. capital flows into China's biotechnology sector harm national security, to be shared with specified congressional committees.
The bill primarily affects U.S. companies, investors, and biotechnology firms engaged in licensing, joint ventures, or investment transactions with entities tied to China, subjecting certain biotech dealings to federal review similar to existing rules for semiconductors and artificial intelligence.
Introduced June 2, 2026, by Rep. John Moolenaar with Rep. Debbie Dingell, the bill has been referred to the House Committee on Financial Services. It has not yet received committee action, floor votes, or Senate consideration.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
This bill is in the first stage of the legislative process. It was introduced into Congress on June 2, 2026. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
Common questions
- What does H.R. 9102 do?
- H.R. 9102, the Biotech Investment National Security Act of 2026 (BINSA Act), would amend the Defense Production Act of 1950 to add biotechnology to the list of technology areas subject to outbound investment screening. Specifically, it expands the definitions of "prohibited technology" and "notifiable technology" to include research, development, manufacturing, or commercialization of pharmaceutical products, biological products, and therapeutic compounds, including drug discovery platforms, clinical research capabilities, biologics manufacturing, and related intellectual property. It also adds licensing a prohibited technology from a covered foreign person as a covered transaction type. The bill directs the Treasury Secretary, within one year and after consulting with the Departments of Health and Human Services and Defense and the Director of National Intelligence, to issue a rule further defining the biotechnology sector for these purposes, prioritizing licensing deals, joint ventures, and equity investments involving drug discovery, clinical development, and manufacturing know-how, while excluding agricultural biotechnology, unrelated industrial fermentation, and basic academic research. It also requires a Defense Department report within 60 days assessing whether U.S. capital flows into China's biotechnology sector harm national security, to be shared with specified congressional committees. The bill primarily affects U.S. companies, investors, and biotechnology firms engaged in licensing, joint ventures, or investment transactions with entities tied to China, subjecting certain biotech dealings to federal review similar to existing rules for semiconductors and artificial intelligence. Introduced June 2, 2026, by Rep. John Moolenaar with Rep. Debbie Dingell, the bill has been referred to the House Committee on Financial Services. It has not yet received committee action, floor votes, or Senate consideration.
- Has H.R. 9102 become law?
- Not yet. As of 2 Jun 2026, H.R. 9102 is introduced.
- Who sponsored H.R. 9102?
- H.R. 9102 was sponsored by Rep. John Moolenaar [R-MI2] (Republican-MI), with 1 cosponsor.
- What's the latest action on H.R. 9102?
- Introduced (2 Jun 2026).
Related bills in Science, Technology, Communications
Open-Source AI Leadership Act
ITS Codification Act
Memory Chip Competitiveness Assessment Act of 2026
AI for Secure Networks Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.